Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
47 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Bionomics Ltd - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Bionomics Ltd - Product Pipeline Review - 2016', provides an overview of the Bionomics Ltd's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Bionomics Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Bionomics Ltd - The report provides overview of Bionomics Ltd including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Bionomics Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Bionomics Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Bionomics Ltd's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Bionomics Ltd - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Bionomics Ltd's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Bionomics Ltd Snapshot 6 Bionomics Ltd Overview 6 Key Facts 6 Bionomics Ltd - Research and Development Overview 7 Key Therapeutic Areas 7 Bionomics Ltd - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 Bionomics Ltd - Pipeline Products Glance 14 Bionomics Ltd - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 Bionomics Ltd - Early Stage Pipeline Products 16 IND/CTA Filed Products/Combination Treatment Modalities 16 Preclinical Products/Combination Treatment Modalities 17 Bionomics Ltd - Drug Profiles 18 BL-011256 - Drug Profile 18 Product Description 18 Mechanism Of Action 18 R&D Progress 18 BNC-101 - Drug Profile 19 Product Description 19 Mechanism Of Action 19 R&D Progress 19 BNC-105 - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 BNC-164 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 BNC-210 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 BNC-420 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Drug for Dyskinesia - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Drug for Pain - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Drugs for Solid Tumors - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Drugs to Inhibit MELK for Solid Tumors - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Small Molecules to Agonize GABA-A Receptor For Epilepsy - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Bionomics Ltd - Pipeline Analysis 39 Bionomics Ltd - Pipeline Products by Target 39 Bionomics Ltd - Pipeline Products by Route of Administration 40 Bionomics Ltd - Pipeline Products by Molecule Type 41 Bionomics Ltd - Pipeline Products by Mechanism of Action 42 Bionomics Ltd - Dormant Projects 43 Bionomics Ltd - Discontinued Pipeline Products 44 Discontinued Pipeline Product Profiles 44 Drug to Inhibit RET Kinase for Lung and Thyroid Cancer 44 Bionomics Ltd - Locations And Subsidiaries 45 Head Office 45 Other Locations & Subsidiaries 45 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 46 Disclaimer 47
List of Tables
Bionomics Ltd, Key Facts 6 Bionomics Ltd - Pipeline by Indication, 2016 8 Bionomics Ltd - Pipeline by Stage of Development, 2016 10 Bionomics Ltd - Monotherapy Products in Pipeline, 2016 11 Bionomics Ltd - Out-Licensed Products in Pipeline, 2016 12 Bionomics Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016 13 Bionomics Ltd - Phase II, 2016 14 Bionomics Ltd - Phase I, 2016 15 Bionomics Ltd - IND/CTA Filed, 2016 16 Bionomics Ltd - Preclinical, 2016 17 Bionomics Ltd - Pipeline by Target, 2016 39 Bionomics Ltd - Pipeline by Route of Administration, 2016 40 Bionomics Ltd - Pipeline by Molecule Type, 2016 41 Bionomics Ltd - Pipeline Products by Mechanism of Action, 2016 42 Bionomics Ltd - Dormant Developmental Projects,2016 43 Bionomics Ltd - Discontinued Pipeline Products, 2016 44 Bionomics Ltd, Subsidiaries 45
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.